BioVie Inc.(BIVI)Earnings, Financials & Key Ratios
BIVI•NASDAQ
$1.54
$2M mkt cap·Price updated May 7, 2026
AboutBioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.Show more
- Revenue$0
- EBITDA-$18M+44.2%
- Net Income-$18M+45.4%
- EPS (Diluted)-12.12+83.4%
- ROE-101.64%+51.2%
- Debt/Equity0.02-95.3%
- Interest Coverage-54.30-388.3%
BIVI Key Insights
BioVie Inc. (BIVI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BIVI Price & Volume
BioVie Inc. (BIVI) stock price & volume — 10-year historical chart
Loading chart...
BIVI Growth Metrics
BioVie Inc. (BIVI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM27.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.29%
Return on Capital
10 Years-443.46%
5 Years-703.82%
3 Years-175.32%
Last Year-102.81%
BIVI Peer Comparison
BioVie Inc. (BIVI) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 NRXP | 84.71M | 3.06 | -2.28 | -157.28% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 | |||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 CORT | 5.48B | 51.05 | 62.26 | 12.79% | 6.23% | 7.5% | 0.01 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 AVXL | 289.14M | 3.12 | -5.78 | -31.55% |
Compare BIVI vs Peers
BioVie Inc. (BIVI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIVI Income Statement
BioVie Inc. (BIVI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 229.38K | 172.03K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -229.38K▲ 0% | -172.03K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 1.55M | 2.37M | 2.5M | 2.69M | 138.05M | 27.25M | 45.08M | 32.18M | 17.84M | 18.03M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 857.88K | 1.77M | 1.26M | 0 | 0 | 0 | 11.55M | 0 | 8.57M | 6.61M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 466.35K | 370.85K | 1.01M | 1.15M | 133.19M | 17.26M | 33.3M | 23.1M | 9.27M | 9.78M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 222.93K | 0 | 0 | 1.54M | 4.87M | 9.99M | 229.38K | 9.08M | 0 | 1000K |
| Operating Income | -1.55M▲ 0% | -2.37M▼ 52.6% | -2.5M▼ 5.3% | -2.69M▼ 7.8% | -138.05M▼ 5026.6% | -27.25M▲ 80.3% | -45.08M▼ 65.4% | -32.18M▲ 28.6% | -18.07M▲ 43.9% | -18.2M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -259.7% | -52.64% | -5.27% | -7.84% | -5026.62% | 80.26% | -65.41% | 28.62% | 43.86% | - |
| EBITDA | -1.32M | -2.14M | -2.27M | -2.46M | -137.82M | -27.02M | -44.85M | -31.95M | -17.84M | -17.97M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -247.68% | -61.75% | -5.83% | -8.64% | -5494.62% | 80.39% | -65.97% | 28.76% | 44.17% | 24.21% |
| D&A (Non-Cash Add-back) | 229.38K | 229.38K | 229.38K | 229.38K | 230K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K |
| EBIT | -1.55M | -2.37M | -2.5M | -2.69M | -138.05M | -27.25M | -45.96M | -32.18M | -17.21M | -17.66M |
| Net Interest Income | 0 | -40.96K | 886 | -4.77M | -537.48K | -2.12M | -3.74M | -1.76M | 520.31K | 756.31K |
| Interest Income | 0 | 0 | 1.16K | 0 | 21.97K | 44.08K | 562.26K | 1.14M | 853.03K | 774.26K |
| Interest Expense | 0 | 40.96K | 273 | 4.77M | 559.46K | 2.16M | 4.3M | 2.89M | 332.72K | 17.95K |
| Other Income/Expense | 222.94K | -40.96K | 52.29K | -13.98M | 7.8M | 1.17M | -5.18M | 59.05K | 524.08K | 763.6K |
| Pretax Income | -1.33M▲ 0% | -2.41M▼ 81.3% | -2.44M▼ 1.3% | -16.68M▼ 582.4% | -130.25M▼ 681.0% | -26.08M▲ 80.0% | -50.26M▼ 92.7% | -32.12M▲ 36.1% | -17.54M▲ 45.4% | -17.48M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.33M▲ 0% | -2.41M▼ 81.3% | -2.44M▼ 1.3% | -16.68M▼ 582.4% | -130.25M▼ 681.0% | -26.08M▲ 80.0% | -50.26M▼ 92.7% | -32.12M▲ 36.1% | -17.54M▲ 45.4% | -17.48M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -208.16% | -81.29% | -1.28% | -582.36% | -681.02% | 79.97% | -92.67% | 36.09% | 45.39% | 27.99% |
| Net Income (Continuing) | -1.33M | -2.41M | -2.44M | -16.68M | -130.25M | -26.08M | -50.26M | -32.12M | -17.54M | -17.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -186.10▲ 0% | -317.70▼ 70.7% | -98.20▲ 69.1% | -685.20▼ 597.8% | -1482.30▼ 116.3% | -106.00▲ 92.8% | -154.70▼ 45.9% | -73.05▲ 52.8% | -12.12▲ 83.4% | -2.21▲ 0% |
| EPS Growth % | -200.65% | -70.71% | 69.09% | -597.76% | -116.33% | 92.85% | -45.94% | 52.78% | 83.41% | 87.29% |
| EPS (Basic) | -186.10 | -317.70 | -98.20 | -685.20 | -1482.30 | -106.00 | -154.70 | -73.05 | -12.12 | - |
| Diluted Shares Outstanding | 7.15K | 7.66K | 25.4K | 49.3K | 124.03K | 246.63K | 324.83K | 451.85K | 1.48M | 7.92M |
| Basic Shares Outstanding | 7.1K | 7.5K | 24.9K | 49.3K | 124.03K | 246.63K | 324.83K | 451.85K | 1.48M | 7.92M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BIVI Balance Sheet
BioVie Inc. (BIVI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.14K | 45.8K | 674.07K | 412.98K | 4.61M | 18.78M | 34.04M | 24.05M | 20.7M | 21.79M |
| Cash & Short-Term Investments | 5.14K | 45.8K | 339.92K | 37.2K | 4.51M | 18.64M | 33.94M | 23.84M | 17.54M | 20.54M |
| Cash Only | 5.14K | 45.8K | 339.92K | 37.2K | 4.51M | 18.64M | 19.46M | 23.84M | 17.54M | 20.54M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 14.48M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.1M | 195.48K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 334.15K | 375.79K | 0 | 0 | 102.53K | 204.39K | 0 | 1.06M |
| Total Non-Current Assets | 2.36M | 2.13M | 1.9M | 1.67M | 1.44M | 1.33M | 1.06M | 1.16M | 863.71K | 711.86K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 118.25K | 80.79K | 406.73K | 339.65K | 302.5K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K |
| Intangible Assets | 2.01M | 1.78M | 1.55M | 1.33M | 1.1M | 866.47K | 637.1K | 407.72K | 178.34K | 63.65K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 4.56K | 0 | 0 | 0 | 0 |
| Total Assets | 2.36M▲ 0% | 2.18M▼ 8.0% | 2.57M▲ 18.3% | 2.08M▼ 19.1% | 6.05M▲ 190.2% | 20.11M▲ 232.7% | 35.1M▲ 74.5% | 25.21M▼ 28.2% | 21.56M▼ 14.5% | 22.5M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -13.05% | -7.98% | 18.34% | -19.05% | 190.16% | 232.65% | 74.52% | -28.19% | -14.46% | -22.99% |
| Total Current Liabilities | 630.97K | 1.24M | 443.48K | 23.52M | 996.37K | 4.17M | 14.49M | 9.35M | 2.27M | 3.01M |
| Accounts Payable | 470.97K | 884.21K | 443.48K | 1.26M | 996.37K | 2.44M | 0 | 0 | 2.2M | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 3.5K | 2K |
| Short-Term Debt | 35K | 0 | 0 | 848.54K | 0 | 0 | 9.11M | 5.7M | 0 | 82.4K |
| Deferred Revenue (Current) | -35K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 21.41M | 0 | 1.11M | 5.34M | 3.59M | 0 | 2.92M |
| Current Ratio | 0.01x | 0.04x | 1.52x | 0.02x | 4.62x | 4.50x | 2.35x | 2.57x | 9.10x | 9.10x |
| Quick Ratio | 0.01x | 0.04x | 1.52x | 0.02x | 4.62x | 4.50x | 2.35x | 2.57x | 9.10x | 9.10x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 575.92K | 825.92K | 0 | 62.5K | 0 | 12.27M | 5.27M | 349.89K | 275.43K | 232.52K |
| Long-Term Debt | 575.92K | 825.92K | 0 | 62.5K | 0 | 12.14M | 5.23M | 0 | 0 | 232.52K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 87.41K | 42.51K | 349.89K | 275.43K | 1.06M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 48.38K | 0 | 0 | 0 | -486.89K |
| Total Liabilities | 1.21M | 2.06M | 443.48K | 23.58M | 996.37K | 16.44M | 19.76M | 9.7M | 2.55M | 3.24M |
| Total Debt | 35K | 825.92K | 0 | 911.04K | 0 | 12.26M | 14.42M | 6.11M | 349.89K | 547.43K |
| Net Debt | 29.86K | 780.12K | -339.92K | 873.85K | -4.51M | -6.38M | -5.04M | -17.73M | -17.19M | -19.99M |
| Debt / Equity | 0.03x | 7.43x | - | - | - | 3.34x | 0.94x | 0.39x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.11x |
| Interest Coverage | - | -57.91x | -9146.52x | -0.56x | -246.77x | -12.60x | -10.48x | -11.12x | -54.30x | -984.01x |
| Total Equity | 1.16M▲ 0% | 111.2K▼ 90.4% | 2.13M▲ 1816.3% | -21.5M▼ 1108.9% | 5.05M▲ 123.5% | 3.67M▼ 27.3% | 15.34M▲ 317.9% | 15.51M▲ 1.1% | 19.01M▲ 22.6% | 19.27M▲ 0% |
| Equity Growth % | -39.6% | -90.39% | 1816.3% | -1108.9% | 123.49% | -27.31% | 317.88% | 1.08% | 22.61% | 95.58% |
| Book Value per Share | 161.83 | 14.52 | 83.91 | -436.12 | 40.72 | 14.88 | 47.23 | 34.32 | 12.87 | 2.43 |
| Total Shareholders' Equity | 1.16M | 111.2K | 2.13M | -21.5M | 5.05M | 3.67M | 15.34M | 15.51M | 19.01M | 19.27M |
| Common Stock | 9.19K | 9.85K | 50.73K | 520 | 2.23K | 2.5K | 3.64K | 6.23K | 7.48K | 754 |
| Retained Earnings | -2.34M | -4.77M | -7.26M | -41.04M | -224.89M | -250.97M | -301.23M | -334.23M | -352.14M | -363.34M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -27 | -29 | -29 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 176.59K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BIVI Cash Flow Statement
BioVie Inc. (BIVI) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -623.62K | -621.34K | -2.5M | -1.63M | -10.45M | -18.99M | -40.25M | -27.95M | -19.03M | -19.03M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -281.11% | 0.36% | -302.61% | 34.91% | -541.99% | -81.68% | -111.96% | 30.58% | 31.92% | 102.45% |
| Net Income | -1.33M | -2.41M | -2.44M | -16.68M | -130.25M | -26.08M | -50.26M | -32.12M | -17.54M | -17.48M |
| Depreciation & Amortization | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K |
| Stock-Based Compensation | 92.05K | 893.48K | 64.86K | 24.85K | 3.02M | 6.19M | 6.38M | 4.66M | 2.47M | 977.61K |
| Deferred Taxes | 0 | 0 | 51.4K | 0 | -8.34M | 0 | -1.03B | 0 | 0 | 0 |
| Other Non-Cash Items | 550.81K | 26.52K | 49K | 14.02M | 124.87M | -2.08M | 1.04B | -627.14K | 212.09K | 2.2M |
| Working Capital Changes | 385.63K | 642.4K | -451.93K | 774.09K | 19.47K | 2.75M | -270.44K | -86.84K | -4.4M | -296.89K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.1M | -2.1M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 350.67K | 413.23K | -117.78K | 0 | 0 | 0 | 0 | 0 | 0 | 723.02K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | -14.3M | 14.53M | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 505K | 662K | 2.8M | 1.33M | 14.93M | 33.12M | 55.37M | 17.8M | 12.73M | 10.46M |
| Debt Issued (Net) | 0 | -35K | -244.3K | 1.33M | -1.39M | 14.61M | 0 | -10M | -5.85M | 0 |
| Equity Issued (Net) | 0 | 447K | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | -48.66K | 0 | 0 | 0 | 0 | 0 | 0 | -43.54K |
| Share Repurchases | 0 | 0 | -1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 505K | 250K | 3.04M | 0 | 685.3K | 0 | 2.24K | 0 | 2.9M | 43.54K |
| Net Change in Cash | -118.62K▲ 0% | 40.66K▲ 134.3% | 294.12K▲ 623.4% | -302.73K▼ 202.9% | 4.47M▲ 1578.0% | 14.13M▲ 215.8% | 819.17K▼ 94.2% | 4.38M▲ 435.0% | -6.3M▼ 243.7% | -3.86M▲ 0% |
| Free Cash Flow | -623.62K▲ 0% | -621.34K▲ 0.4% | -2.5M▼ 302.6% | -1.63M▲ 34.9% | -10.45M▼ 542.0% | -18.99M▼ 81.7% | -40.25M▼ 112.0% | -27.95M▲ 30.6% | -19.03M▲ 31.9% | -14.32M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -281.11% | 0.36% | -302.61% | 34.91% | -541.99% | -81.68% | -111.96% | 30.58% | 31.92% | 34.96% |
| FCF per Share | -87.20 | -81.11 | -98.50 | -33.03 | -84.28 | -77.00 | -123.92 | -61.85 | -12.88 | -12.88 |
| FCF Conversion (FCF/Net Income) | 0.47x | 0.26x | 1.02x | 0.10x | 0.08x | 0.73x | 0.80x | 0.87x | 1.08x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 3.09K | 22.18K | 964.24K | 2.11M | 0 | 183.93K | 9.99K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BIVI Key Ratios
BioVie Inc. (BIVI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -86.62% | -380.44% | -218.01% | - | -2579.03% | -598.18% | -528.7% | -208.26% | -101.64% | -90.72% |
| Return on Invested Capital (ROIC) | -77.98% | -171.18% | -139.64% | - | - | - | -890.52% | -597.91% | - | -13751.57% |
| Debt / Equity | 0.03x | 7.43x | - | - | - | 3.34x | 0.94x | 0.39x | 0.02x | 0.02x |
| Interest Coverage | - | -57.91x | -9146.52x | -0.56x | -246.77x | -12.60x | -10.48x | -11.12x | -54.30x | -984.01x |
| FCF Conversion | 0.47x | 0.26x | 1.02x | 0.10x | 0.08x | 0.73x | 0.80x | 0.87x | 1.08x | 0.82x |
BIVI Frequently Asked Questions
BioVie Inc. (BIVI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioVie Inc. (BIVI) grew revenue by 0.0% over the past year. Growth has been modest.
BioVie Inc. (BIVI) reported a net loss of $17.5M for fiscal year 2025.
Dividend & Returns
BioVie Inc. (BIVI) has a return on equity (ROE) of -101.6%. Negative ROE indicates the company is unprofitable.
BioVie Inc. (BIVI) had negative free cash flow of $14.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More BIVI
BioVie Inc. (BIVI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates